Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 180

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 180
---
 26

    —

    26

    Net loss

    —

    —

    —

    —

    —

    (84,689
    )

    (84,689
    )

    Balance, December 31, 2024

    42,510,708

    $
    486,674

    $
    10

    $
    82,191

    $
    54

    $
    (417,798
    )
     
    $
    151,131

The accompanying notes are an integral part of these consolidated financial statements 

104

Repare Therapeutics Inc. 

Consolidated Statements of Cash Flows 

(In thousands of U.S. dollars) 

    Year Ended December 31,

    2024

    2023

    Cash Flows From Operating Activities:

    Net loss for the year
     
    $
    (84,689
    )
     
    $
    (93,796
    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Share-based compensation expense

    23,170

    25,063

    Depreciation expense

    1,921

    1,951

    Non-cash lease expense

    2,359

    2,194

    Foreign exchange loss

    8

    78

    Net accretion of marketable securities

    (5,157
    )

    (7,465
    )

    Changes in operating assets and liabilities:

    Prepaid expenses

    (1,263
    )

    969

    Other current receivables

    2,716

    (216
    )

    Other non-current assets

    217

    101

    Accounts payable

    1,229

    1,934

    Accrued expenses and other current liabilities

    (4,222
    )

    2,412

    Operating lease liabilities, current portion

    (986
    )

    151

    Income taxes

    1,529

    (14,329
    )

    Operating lease liabilities, net of current portion

    (1,325
    )

    (2,373
    )

    Deferred revenue

    (11,952
    )

    (43,832
    )

    Net cash used in operating activities

    (76,445
    )

    (127,158